ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AMLX vs XENE // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Amylyx Pharmaceuticals Inc. (NASDAQ) VS. Xenon Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: AMLX 2 — XENE 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMLX VS. XENE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AMLX XENE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -3.43% -7.70% +4.27 AMLX /fcf-yield <GO>
Operating Margin — -36.70% — TIE /operating-margins <GO>
Net Profit Margin — -34.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 7.70% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 26.00 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 5/9 -2.00 XENE /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 51.9 44.3 +7.60 AMLX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.10 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 29.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.62B $3.62B -$2.1M XENE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AMLX REV XENE REV AMLX GROSS % XENE GROSS % AMLX FCF XENE FCF
FY 2025 $429.2M $1.04B — — -$123.5M -$279.9M
FY 2024 $87.4M $782.0M 93.2% — -$167.8M -$184.5M
FY 2023 $380.8M $599.4M — — $11.9M -$151.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMLX // BETA —
XENE // BETA 1.10